• Chemring’s US based subsidiary, Chemring Sensors and Electronic Systems, has been down selected as one of the suppliers on the first stream of the Next Generation Chemical Detector (NGCD1).

  • The National Library of Medicine ToxTutor, a self-paced tutorial covering key principles of toxicology for users of the National Library of Medicine (NLM) chemical and toxicology databases, has recently added new content and topics to it’s every growing catalogue.

  • Alluviam has recently announced the release of the HazMasterG3, adding adaptive, mission specific CBRNE UI, and other advanced tools.

    Changing mission requirements, from responding to improvised warfare agent contamination in Syria, site exploitation of clandestine labs, or responding to hazmat incidents all require unique tools and techniques to successfully prosecute these scenarios.  With HazMasterG3’s new release, the system can rapidly adapt to these and other situations by dynamically adapting the user interface to meet the needs of any mission scenario

  • Public Health England (PHE) confirmed on September 8th that an individual had been diagnosed with Monkeypox in the UK, the first time such a diagnosis has been made.

    Monkeypox is a rare infection and does not spread easily between individuals and PHE has made sure to issue information to this effect.

  • Bertin Technologies has been selected, in a consortium with Thales CS, by the Ministry of the Armed Forces for the upstream research market “Platform for the Integration of Innovative Technologies in the Domain of Biological and Chemical Analysis “(PI ABC),

  • Chemring Sensors and Electronic Systems, has been notified that it has been down selected as one of the suppliers on the first stream of the Next Generation Chemical Detector

  • Rigaku Analytical Devices unveils new handheld Raman analyser to redefine handheld 1064nm Raman for chemical threat identification

  • Sarcos Robotics announced a $30M Series B funding raise to help advance the deployment of its Guardian S mobile IoT inspection and surveillance robot, as well as prepare for the launch of the commercial versions of its autonomously powered, full-body industrial exoskeleton Guardian XO product line.

  • Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced on friday that it was awarded an Other Transaction Agreement (OTA) to support the Joint Project Manager Medical Countermeasure Systems (JPM-MCS) for advanced biologics manufacturing services—specifically, to manufacture an anti-Ebola monoclonal antibody (mAb).

    The award was made possible through collaborative funding between JPEO CBRND and the Defense Advanced Research Projects Agency (DARPA). The antibody, designated mAb114, was developed at the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID) with the National Institutes of Health, in part through funding previously provided by DARPA. The VRC is a collaborator with JPM-MCS, DARPA, and Ology Bioservices on this program. Including optional work, the agreement has a value of $8.4 million.

  • CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. under which they will receive up to USD$36 million to advance the development and manufacture of a vaccine against the Lassa virus.

  • Follow us on Twitter
  • Subscribe to CBRNe news